Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1987
Projections of cancer risks attributable to future exposure to asbestosJ A MauskopfRisk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1991
Estimating the value of avoiding morbidity and mortality from foodborne illnessesJ A Mauskopf, M T FrenchThe American Journal of Cardiology|December 15, 1991
Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicityJ A Mauskopf, T L WengerAmerican Journal of Public Health|November 1, 1992
A quality-of-life method for estimating the value of avoided morbidityM T French, J A MauskopfClinical Therapeutics|May 24, 2000
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmineA B Hauber, A Gnanasakthy, J A MauskopfPharmacotherapy|September 1, 1995
Cost-consequence models for varicella-zoster virus infectionsJ E Paul, J A Mauskopf, L BellPharmacoeconomics|January 6, 2000
A pharmacoeconomic model for the treatment of influenzaJ A Mauskopf, S C Cates, A D GriffinNeurology|October 22, 1998
Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsyM A Markowitz, J A Mauskopf, M T HalpernPharmacoeconomics|January 9, 2001
Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practiceJ A Mauskopf, A Richter, L Annemans, et al.Journal of Occupational Medicine. : Official Publication of the Industrial Medical Association|June 1, 1991
Benefit-cost analysis of hepatitis B vaccine programs for occupationally exposed workersJ A Mauskopf, C J Bradley, M T FrenchPageof 3